FORXIGA® receives regulatory approval in Japan for the treatment of type 2 diabetes

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes. The FORXIGA application was submitted to the MHLW by Bristol-Myers Squibb K.K.. AstraZeneca and Ono Pharmaceutical entered into an agreement to co-promote FORXIGA on 3 December 2013.

Fouzia Laghrissi-Thode, Vice President, Global Product Portfolio Strategy for Cardiovascular and Metabolism, said: “In collaboration with our partner Ono, we are pleased to provide FORXIGA as a new treatment option for patients in Japan, where there are an estimated 9.5 million people living with type 2 diabetes. The approval of FORXIGA reinforces AstraZeneca’s focus on both diabetes and Japan as two of our key growth drivers."

FORXIGA is a highly selective and reversible inhibitor of sodium-glucose cotransporter 2 that works independently of insulin to help remove excess glucose from the body. Currently approved in more than 40 countries globally, FORXIGA was the first SGLT2 inhibitor in the world to gain regulatory approval to treat type 2 diabetes in Europe in November 2012. It was approved by the US Food and Drug Administration for the treatment of adults with type 2 diabetes on 8 January 2014, supported by a robust clinical development programme comprised of 24 clinical studies evaluating safety and efficacy of FORXIGA. The studies included more than 11,000 adults with type 2 diabetes, with more than 6,000 patients treated with dapagliflozin. The on-going global clinical development programme also includes a cardiovascular outcomes trial which aims to enroll more than 17,000 patients.

– ENDS –

NOTES TO EDITORS

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. is a R&D-oriented pharmaceutical company specialised in creating innovative medicines in specific areas and is headquartered in Osaka, Japan, putting focus in the area of diabetes and oncology. For more information, please visit www.ono.co.jp/eng/index.html

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Michele Meixell                            +1 302 885 2677 (US)

Jacob Lund                                 +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor                           + 1 302 886 1842     mob: +1 302 357 4882

Anthony Brown                           +44 20 7604 8067   mob: +44 7585 404943

Jens Lindberg                             +44 20 7604 8414   mob: +44 7557 319729

Taggar: